tetano
Editor, Senior Moderator
Vaccine
. 2020 Aug 7;S0264-410X(20)31005-7.
doi: 10.1016/j.vaccine.2020.07.063. Online ahead of print.
Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19
Anke L Stuurman[SUP] 1 [/SUP], Kaatje Bollaerts[SUP] 1 [/SUP], Maria Alexandridou[SUP] 1 [/SUP], Jorne Biccler[SUP] 1 [/SUP], Javier D?ez Domingo[SUP] 2 [/SUP], Hanna Nohynek[SUP] 3 [/SUP], Caterina Rizzo[SUP] 4 [/SUP], Topi Turunen[SUP] 2 [/SUP], Margarita Riera-Montes[SUP] 5 [/SUP], DRIVE Public Partners
Affiliations
Abstract
The DRIVE project aims to establish a sustainable network to estimate brand-specific influenza vaccine effectiveness (IVE) annually. DRIVE is a public-private partnership launched in response to EMA guidance that requires effectiveness evaluation from manufacturers for all individual influenza vaccine brands every season. IVE studies are conducted by public partners in DRIVE. Private partners (vaccine manufacturers from the European Federation of Pharmaceutical Industries and Association (EFPIA)) provide written feedback moderated by an independent scientific committee. Test-negative design (TND) case-control studies (4 in primary care and five in hospital) were conducted in six countries in Europe during the 2018/19 season. Site-specific confounder-adjusted vaccine effectiveness (VE) estimates for any vaccine exposure were calculated by age group (<18 years
, 18-64y and 65 + y) and pooled by setting (primary care, hospital) through random effects meta-analysis. In addition, one population-based cohort study was conducted in Finland. TND studies included 3339 cases and 6012 controls; seven vaccine brands were reported. For ages 65 + y, pooled VE against any influenza strain was estimated at 27% (95%CI 6-44) in hospital setting. Sample size was insufficient for meaningful IVE estimates in other age groups, in the primary care setting, or by vaccine brand. The population-based cohort study included 274,077 vaccinated and 494,337 unvaccinated person-years, two vaccine brands were reported. Brand-specific IVE was estimated for Fluenz Tetra (36% [95%CI 24-45]) for ages 2-6y, Vaxigrip Tetra (54% [43-62]) for ages 6 months to 6y, and Vaxigrip Tetra (30% [25-35]) for ages 65 + y. The results presented are from the second influenza season covered by the DRIVE network. While sample size from the pooled TND studies was still too low for precise (brand-specific) IVE estimates, the network has approximately doubled in size compared to the pilot season. Taking measures to increase sample size is an important focus of DRIVE for the coming years.
Keywords: Brand; Effectiveness; European Union; Influenza; Public–private partnerships; Vaccines.
. 2020 Aug 7;S0264-410X(20)31005-7.
doi: 10.1016/j.vaccine.2020.07.063. Online ahead of print.
Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19
Anke L Stuurman[SUP] 1 [/SUP], Kaatje Bollaerts[SUP] 1 [/SUP], Maria Alexandridou[SUP] 1 [/SUP], Jorne Biccler[SUP] 1 [/SUP], Javier D?ez Domingo[SUP] 2 [/SUP], Hanna Nohynek[SUP] 3 [/SUP], Caterina Rizzo[SUP] 4 [/SUP], Topi Turunen[SUP] 2 [/SUP], Margarita Riera-Montes[SUP] 5 [/SUP], DRIVE Public Partners
Affiliations
- PMID: 32778474
- DOI: 10.1016/j.vaccine.2020.07.063
Abstract
The DRIVE project aims to establish a sustainable network to estimate brand-specific influenza vaccine effectiveness (IVE) annually. DRIVE is a public-private partnership launched in response to EMA guidance that requires effectiveness evaluation from manufacturers for all individual influenza vaccine brands every season. IVE studies are conducted by public partners in DRIVE. Private partners (vaccine manufacturers from the European Federation of Pharmaceutical Industries and Association (EFPIA)) provide written feedback moderated by an independent scientific committee. Test-negative design (TND) case-control studies (4 in primary care and five in hospital) were conducted in six countries in Europe during the 2018/19 season. Site-specific confounder-adjusted vaccine effectiveness (VE) estimates for any vaccine exposure were calculated by age group (<18 years
, 18-64y and 65 + y) and pooled by setting (primary care, hospital) through random effects meta-analysis. In addition, one population-based cohort study was conducted in Finland. TND studies included 3339 cases and 6012 controls; seven vaccine brands were reported. For ages 65 + y, pooled VE against any influenza strain was estimated at 27% (95%CI 6-44) in hospital setting. Sample size was insufficient for meaningful IVE estimates in other age groups, in the primary care setting, or by vaccine brand. The population-based cohort study included 274,077 vaccinated and 494,337 unvaccinated person-years, two vaccine brands were reported. Brand-specific IVE was estimated for Fluenz Tetra (36% [95%CI 24-45]) for ages 2-6y, Vaxigrip Tetra (54% [43-62]) for ages 6 months to 6y, and Vaxigrip Tetra (30% [25-35]) for ages 65 + y. The results presented are from the second influenza season covered by the DRIVE network. While sample size from the pooled TND studies was still too low for precise (brand-specific) IVE estimates, the network has approximately doubled in size compared to the pilot season. Taking measures to increase sample size is an important focus of DRIVE for the coming years.Keywords: Brand; Effectiveness; European Union; Influenza; Public–private partnerships; Vaccines.